IL6 and cancer: Given our findings indicating that IL-6 is not required for maintenance of acquired cetuximab resistance in the PE/CA-PJ49 CtxR cells, we elected to use an unbiased approach, next-generation DNA sequencing using a targeted gene panel (UCSF500 Cancer Gene Panel) [38], to identify potential mediators of cetuximab resistance in these models.